secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001140361-24-017141
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports positive Phase 2 NIU data; authorizes $1.5B buyback, repurchases Sumitomo's 9% stake
--------------------------------------------------------------------------------

- Phase 2 NEPTUNE: brepocitinib 45mg arm had 29% Treatment Failure at week 24 (vs 44% for 15mg), best observed in NIU studies.
- All secondary endpoints positive; 43% of patients with baseline macular edema achieved resolution by week 24 on 45mg.
- Board authorized up to $1.5B share repurchase; $648.4M to buy Sumitomo's 71.3M shares at $9.10, reducing shares outstanding by ~9%.
- Phase 3 program in NIU to start H2 2024; Phase 3 dermatomyositis study fully enrolled Q3 2024, data expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/0001140361-24-017141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/ef20025692_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-017141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer